Page 116 - Eceptor News Today

Androgen receptor (AR) signaling affects response to BRAF/MEK inhibitor therapy in both males and females with melanoma, researchers from The University of Texas MD Anderson Cancer Center showed in a study published today in Nature.

Clinical data builds upon body of evidence suggesting EXS-21546 is a highly potent and selective A2AR antagonist with low CNS exposure Exscientia anticipates initiating Phase 1b/2 in patients with

Researchers assessed the role of adenoside diphosphate (ADP)-ribosylation factor 6 (ARF6) in SARS-CoV-2 infection.

Researchers assessed the interactions between SARS-CoV-2 and ACE2.

Researchers described potential mechanisms of coronaviruses that could lead to DNA damage and the potential link between SARS-CoV-2 activity and such mechanisms.

Fezolinetant significantly reduced the frequency and severity of moderate-to-severe vasomotor symptoms (VMS), or hot flashes, associated with menopause, according to a Phase 3 industry-sponsored study being presented Saturday at ENDO 2022, the Endocrine Society's annual meeting in Atlanta, Ga.

Researchers have successfully treated type 1 diabetes in mice using pancreatic beta-cell, target-specific, chimeric antigen-receptor (CAR) regulatory T cells (Tregs), and demonstrated the feasibility of their approach to treat the human condition according to data being presented Monday, June 13 at ENDO 2022, the Endocrine Society's annual meeting in Atlanta, Ga.

Toronto, Canada (CTV Network) -- A new lab-designed molecule that exploits a weakness in cells can kill a wide range of cancers that are difficult to treat, according to a

A new study published in the journal Reports focused on the hijacking of the pancreatic, endothelial, and gut GABA by SARS-CoV-2 and its associated pathology along with interventions.

Researchers assessed the impact of marijuana use on neonatal outcomes.